A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
NCT ID: NCT04568265
Last Updated: 2021-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
122 participants
INTERVENTIONAL
2020-06-03
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B
NCT03585322
Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients
NCT03332329
Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E
NCT01813487
A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors
NCT04454567
Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
NCT05494528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Part 1 will evaluate the safety, tolerability, and pharmacokinetics of APG-1387 in combination with entecavir, including determination of the maximum tolerated dose (MTD)/ recommended dose in patients with CHB. APG-1387 will be administered once weekly via intravenous infusion for 30 minutes for consecutive 4 weeks. APG-1387 will be escalated at 3 dose cohorts of 12 mg, 20 mg, and 30 mg. Entecavir will be administered orally at 0.5 mg daily for 12 weeks: in combination with APG-1387 for the first 4 weeks, followed by entecavir maintenance monotherapy for additional 8 weeks. The total treatment duration will be 12 weeks.
Part 2 is a randomized, parallel, open-label study to investigate the preliminary anti-HBV efficacy of APG-1387 in combination with entecavir compared with entecavir monotherapy. CHB subjects will be randomly assigned to one of 4 cohorts at 1:1:1:1, including APG-1387 at 3 different doses (12 mg, 20 mg, and 30 mg) in combination with entecavir for 12 weeks, respectively, then continued entecavir monotherapy for additional 12 weeks; and one entecavir monotherapy cohort for 24 weeks. The course of treatment is 24 weeks in all cohorts.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
APG-1387 12 mg combined with entecavir 0.5 mg
APG-1387
Weekly intravenous infusion for 30 minutes
Entecavir 0.5 mg
Taken daily by mouth
APG-1387 20 mg combined with entecavir 0.5 mg
APG-1387
Weekly intravenous infusion for 30 minutes
Entecavir 0.5 mg
Taken daily by mouth
APG-1387 30 mg combined with entecavir 0.5 mg
APG-1387
Weekly intravenous infusion for 30 minutes
Entecavir 0.5 mg
Taken daily by mouth
entecavir 0.5 mg
Entecavir 0.5 mg
Taken daily by mouth
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
APG-1387
Weekly intravenous infusion for 30 minutes
Entecavir 0.5 mg
Taken daily by mouth
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented chronic HBV infection (e.g., HBsAg positive for at least 6 months).
* HBeAg-positive or HBeAg-negative
* Treatment-naïve and treatment-experienced subjects are required to:
1. Treatment-naïve subjects:
* No antiviral therapies including nucleos(t)ide analogues or immunomodulators such as interferon within 180 days prior to screening
* HBV DNA ≥ 2x10˄3 IU/mL for HBeAg negative subjects and ≥ 2x10˄4 IU/mL for HBeAg positive subjects (PCR)
* Alanine transaminase (ALT) ≥ upper limit of normal (ULN) and \< 10 × ULN (and excluding ALT elevation caused by non-HBV reasons such as drug or alcohol consumption)
2. Treatment-experienced subjects:
* Using entecavir \> 180 days prior to screening, and should continue the treatment regimen until enrolled into the study
* HBV DNA less than the lower limit of quantification (LLOQ) or \< 20 IU/mL (PCR)
* ALT \< 1.5 × ULN
* Adequate hematological function:
* White blood cell count (WBC) ≥ 3.5 × 10˄9/L
* Hemoglobin ≥ 120 g/L for males and ≥ 110 g/L for females
* Platelet count ≥ 100 × 10˄9/L
* Adequate renal and liver function:
* Serum creatinine ≤ 1×ULN
* Serum albumin ≥ 35.0g/L
* Urine protein is negative or 1 + (re-examination is required when 1 + or 24-hour urine protein quantification is added when necessary. If it turns negative or is within the normal range, it can be included)
* Estimated creatinine clearance (CLCr) ≥ 50 mL/min based on serum creatinine measured at the screening assessment and actual body weight (calculated creatinine clearance by the Cockcroft-Gault formula)
* Total bilirubin ≤1.5×ULN
* International normalized ratio (INR) ≤ 1.5×ULN
* Alkaline phosphatase ≤ 2.5×ULN
* Female subjects of childbearing potential should have a negative serum pregnancy test within 7 days prior to the first dose
* Subjects and theirs partners are willing to use effective contraception as defined in the protocol during the treatment and for at least 6 months after the last dose of study drug
* Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the subject prior to any study-specific procedures)
* Willingness and ability to comply with study procedures and follow-up examination
Exclusion Criteria
* Syphilis with positive antibody for treponema pallidum
* Subjects with liver disease other than hepatitis B, including but not limited to chronic alcoholic hepatitis, drug-induced liver injury, autoimmune liver disease, hereditary liver disease (such as Wilson's disease), and active hepatitis due to other causes
* History or manifestation of hepatic decompensation (e.g., Child-Pugh Class B or C, or history of ascites, gastrointestinal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis)
* Progressive fibrosis/cirrhosis, defined by liver fibrosis scan ≥ 12 kilopascal (kPa) at screening, or cirrhosis diagnosed by imaging examinations, or Metavir score F3, F4 fibrosis on liver biopsy at any time
* Clinically diagnosed hepatocellular carcinoma, or diagnosis of hepatocellular carcinoma cannot be excluded, or serum alpha-fetoprotein greater than 50 μg/L
* History of malignancy (except cured and no evidence of recurrence of basal cell carcinoma of the skin or situ cervical cancer) or lymphoproliferative disease
* History of neurological or mental disorders, such as epilepsy, dementia, and poor compliance
* Uncontrolled primary diseases of other important organs, such as clear medical history of nervous system, cardiovascular system, urinary system (including chronic or intermittent urinary system diseases), digestive system, respiratory system, endocrine/metabolic and musculoskeletal system, such as poorly controlled diabetes, hypertension, etc., making the investigator consider the subject unsuitable
* QTcB \[QTcB = QT/(RR\^ 0.5); RR is the normalized heart rate value, obtained by dividing 60 by heart rate in seconds; other parameters in milliseconds\] \> 450 milliseconds for men and \> 470 milliseconds for women; any clinically important abnormality in the rhythm, conduction, or morphology of the resting electrocardiogram (ECG) (e.g., complete left bundle branch block, third degree heart block, second degree heart block); congenital long QT syndrome or family history of long QT syndrome
* History of alcoholism (mean daily intake of ethanol ≥ 30 g (male) or ≥ 20 g (female) within 1 year), and drug abuse
* Subjects planning to become pregnant within 1 year, who are pregnant or breastfeeding
* Received or may receive continuous treatment with immunomodulators (e.g., steroids) or biological agents (e.g., monoclonal antibodies, interferons) within 3 months before screening
* Participated in clinical trials within 3 months before screening
* Trauma or major surgical operation within 4 weeks before screening
* Previous treatment with inhibitors of apoptosis proteins
* Any subject considered unsuitable for the trial by the investigator
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ascentage Pharma Group Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yifan Zhai, MD, PhD
Role: STUDY_CHAIR
Ascentage Pharma Group Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou Eighth People's Hospital
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APG1387BC201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.